

Veröffentlichungsliste von (Publication list of)

Christoph Kapitza,

Dr. med.

01.04.11 14:25:27

Wissenschaftliche Originalarbeiten (Original papers, Brief reports)

1. Perera AD, **Kapitza C**, Nosek L, Fishman RS, Shapiro DA, Heise T, Heinemann L.
Absorption and metabolic effect of inhaled insulin: inpatient variability after inhalation via the Aerodose insulin inhaler in patients with type 2 diabetes.
Diabetes Care 25(12):2276-2281, 2002
2. Poll LW, Wittsack HJ, Koch JA, Willers R, Scherer A, **Kapitza C**, Heinemann L, Modder U.
Quantification of total abdominal fat volumes using magnetic resonance imaging.
Eur J Med Res 30:347-352, 2002
3. **Kapitza C**, Ludwig V, Obermaier K, Wientjes KJ, Hoogenberg K, Jungheim K, Heinemann L, Glucose Monitoring Study Group.
Continuous glucose monitoring: reliable measurements for up to 4 days with the SCGM1 system.
Diabetes Technology and Therapeutics 5:609-614, 2003
4. Wilhelm Poll L, Wittsack HJ, Koch JA, Willers R, Cohnen M, **Kapitza C**, Heinemann L, Modder U.
A rapid and reliable semiautomated method for measurement of total abdominal fat volumes using magnetic resonance imaging.
Magn Reson Imaging 21:631-636, 2003
5. Wientjes KJ, Grob U, Hattemer A, Hoogenber K, Jungheim K, **Kapitza C**, Schoonen AJ, Glucose Monitoring Study Group.
Effects of microdialysis catheter insertion into the subcutaneous adipose tissue assessed by the SCGM1 system.
Diabetes Technology and Therapeutics 5:615-620, 2003
6. **Kapitza C**, Heise T, Fishman RS, Shapiro DA, Gopalakrishnan V, Rave K, Bott S, Perera A, Heinemann L.
Impact of particle size and aerosolization time on the metabolic effect of an inhaled insulin aerosol.
Diabetes Technology and Therapeutics 6:119-127, 2004
7. **Kapitza C**, Hompesch M, Scharling B, Heise T.
Intrasubject variability of inhaled insulin in type 1 diabetes: a comparison with subcutaneous insulin.
Diabetes Technology and Therapeutics 6:466-472, 2004

8. Heise T, Nosek L, Ronn BB, Endahl L, Heinemann L, **Kapitza C**, Draeger E. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. *Diabetes* 53:1614-1620, 2004
9. Rave K, Nosek L, Heinemann L, Frick A, Becker R, **Kapitza C**. Dependency of the metabolic effect of sc-injected human regular insulin on intra-abdominal fat in patients with type 2 diabetes. *Horm Metab Res* 36:307-311, 2004
10. Poll L, Wittsack HJ, Willers R, Modder U, Heinemann L, **Kapitza C**, Rave K. Correlation between anthropometric parameters and abdominal fat volumes assessed by a magnetic resonance imaging method in patients with diabetes. *Diabetes Technol Ther.* 6(6):844-9, 2004
11. **Kapitza C**, Rave K, Ostrowski K, Heise T, Heinemann L. Reduced postprandial glycaemic excursion with biphasic insulin Aspart 30 injected immediately before a meal. *Diabetes Medicine* 21:500-501, 2004
12. Wittsack HJ, **Kapitza C**, Cohnen M, Jung G, Heinemann L, Modder U, Poll L. Interactive thresholded volumetry of abdominal fat using breath-hold t1-weighted magnetic resonance imaging. *Rofo* 178(8):810-5, 2006
13. Bott S, Tusek C, Jacobsen LV, Endahl L, Draeger E, **Kapitza C**, Heise T. Insulin detemir under steady-state conditions: no accumulation and constant metabolic effect over time with twice daily administration in subjects with Type 1 diabetes. *Diabet Med.* 23(5):522-8, 2006
14. **Kapitza C**, Fein S, Heinemann L, Schleusener S, Levesque S, Strange P. Basal-Prandial Insulin Delivery in Type 2 Diabetes Mellitus via the V-Go™: A Novel Continuous Subcutaneous Infusion Device. *Journal of Diabetes Science and Technology.* 2008:2(1), 40-46.
15. Nielsen JK, Freckmann G, **Kapitza C**, Ocvirk G, Koelker KH, Kamecke U, Gillen R, Amann-Zalan I, Jendrike N, Christiansen JS, Koschinsky T, Heinemann L. Glucose monitoring by microdialysis: Performance in a multi-center study. *Diabetic Medicine* 26(7):714-21, 2009
16. Nauck MA, Ratner RE, **Kapitza C**, Berria R, Boldrin M, Balena R. Treatment with the human once-weekly GLP-1 analogue taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes mellitus inadequately controlled with metformin alone: a double-blind placebo-controlled study. *Diabetes Care.*2009; 0: dc08-1961v1-0

17. **Kapitza C**, Heise T, Birman P, Jallet K, Ramist J, Balena R.
Pharmacokinetic and pharmacodynamic properties of taspoglutide, a once-weekly, human GLP-1 analogue, after single-dose administration in patients with Type 2 diabetes.
Diabetic Medicine 26(11):1156-64, 2009
18. Heinemann L, Nosek L, **Kapitza C**, Schweitzer MA, Krinelke L.
Changes in basal insulin infusion rates with subcutaneous insulin infusion: time until a change in metabolic effect is induced in patients with type 1 diabetes.
Diabetes Care 32(8):1437-9, 2009
19. **Kapitza C**, Hövelmann U, Nosek L, Kurth HJ, Essenpreis M, Heinemann L.
Continuous Glucose Monitoring during Exercise in Patients with Type 1 Diabetes on Continuous Subcutaneous Insulin Infusion.
J Diabetes Sci Technol. 4(1):123-131, 2010
20. **Kapitza C**, Zijlstra E, Heinemann L, Castelli MC, Riley G, Heise T.
Oral Insulin: A comparison with Subcutaneous Regular Human Insulin in patients with Type 2 Diabetes.
Diabetes Care. 33(6):1288-90, 2010
21. Ratner R, Nauck M, **Kapitza C.**, Asnaghi V, Boldrin M, Balena R.
Safety and tolerability of high doses of taspoglutide, a once-weekly human GLP-1 analogue, in diabetic patients treated with metformin: a randomized double-blind placebo-controlled study
Diabetic Medicine 27 (5):556-62, 2010
22. Arnolds S, Dellweg S, Clair J, Dain MP, Nauck M, Rave K, **Kapitza C.**
Further improvement in postprandial glucose control when adding exenatide (EXE) or sitagliptin (SITA) to combination therapy with insulin glargine (GLAR) and metformin (MET) – a proof-of-concept study
Diabetes Care. 33(7):1509-15, 2010
23. **Kapitza C**, Zdravkovic M, Zijlstra E, Segel S, Heise T, Flint A.
Effect of Three Different Injection Sites on the Pharmacokinetics of the Once-Daily Human GLP-1 Analogue Liraglutide
Journal of Clinical Pharmacology, Jul 29:doi:10.1177/0091270010374474, 2010
24. Arnolds S, Kuglin B, **Kapitza C**, Heise T.
How pharmacokinetic and pharmacodynamic principles pave the way for optimal basal insulin therapy in type 2 diabetes
International Journal of Clinical Practice 64(10): 1415–1424, 2010.
25. Bonadonna RC, Heise T, Arbert-Engels C, **Kapitza C**, Avogaro A, Grimsby J, Zhi J, Grippo JF, Balena R.
Piragliatin (RO4389620), a Novel Glucokinase Activator, Lowers Plasma Glucose Both in the Postabsorptive State and after a Glucose Challenge in Patients with Type 2 Diabetes Mellitus: A Mechanistic Study.
J Clin Endocrinol Metab. 95(11):5028-36, 2010

26. Flint A, **Kapitza C**; Hindsberger C, Zdravkovic M
The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients
Adv Ther. 2011 28(3): 213-26
27. Pettis RJ, Hirsch L, **Kapitza C**, Nosek L, Hövelmann U, Kurth HJ, Sutter DE, Harvey NG, Heinemann L.
Microneedle-based intradermal versus subcutaneous administration of regular human insulin or insulin lispro: pharmacokinetics and postprandial glycemic excursions in patients with type 1 diabetes.
Diabetes Technol Ther. 2011 Apr;13(4):443-50
28. Pettis RJ, Ginsberg B, Hirsch L, Sutter D, Keith S, McVey E, Harvey NG, Hompesch M, Nosek L, **Kapitza C**, Heinemann L.
Intradermal microneedle delivery of insulin lispro achieves faster insulin absorption and insulin action than subcutaneous injection.
Diabetes Technol Ther. 2011 Apr;13(4):435-42.

Buchbeiträge, Briefe, Berichte zu Workshops, Kongressen und Studien

(Articles in books, book chapters, letters etc.)

1. Heinemann L, **Kapitza C**, Starke AAR, Heise T.
Time-action profile of the insulin analogue B28Asp.
Diabetic Medicine 13:683-684 (Brief), 1996
2. Scherbaum WA, Lankisch M, Neufang-Sahr A, **Kapitza C**
Pschyrembel® Wörterbuch Diabetologie.
Walter de Gruyter, 2003
3. Gallwitz B, Creutzfeldt W, Demuth H-U, Göke B, Göke R, Heise T, **Kapitza C**,
Meier JJ, Nauck MA, Ritzel RA.
GLP-1-Therapiepotential bei Diabetes mellitus.
Uni-Med Verlag AG, 2004
4. Gallwitz B, Arnolds S, Creutzfeldt W, Göke B, Göke R, Heise T, **Kapitza C**, Meier
JJ, Nauck MA, Ritzel RA.
GLP-1 als Therapieprinzip bei Typ 2-Diabetes: Inkretin-Mimetika und DPP-4-
Inhibitoren.
Uni-Med Verlag AG, 2. Auflage, 2006

Wissenschaftliche Vorträge auf nationalen oder internationalen Kongressen und Symposien

(scientific oral presentations at national and international congresses and symposia)

1. **Kapitza C**, Nosek L, Leth G, Codony SG, Lindholm A, Heise T.
Biphasic Insulin Aspart provides good metabolic control even when injected postprandially.
Diabetes und Stoffwechsel 10 (Suppl1):67, 2001
2. **Kapitza C**, Trautmann ME, Heise T, Heinemann L, Patterson B.
Daily administration of LY307161 SR (GLP-1 Analog) normalizes blood glucose in type 2 diabetes
Diabetes 51 (Suppl2):A84, 2002
3. **Kapitza C**, Arbit E, Abbas R, Goldberg M, Hompesch M, Heinemann L, Heise T.
Oral insulin: proof of concept in Type 2 diabetic patients.
Diabetologia 46 (Suppl2):16, 2003
4. **Kapitza C**, Arbit E, Abbas R, Goldberg M, Hompesch M, Heinemann L, Heise T.
Oral Insulin: Proof of Concept in Type 2 Diabetic Patients.
Diabetes 52 (Suppl1):159-OR, 2003
5. **Kapitza C**, Nauck MA, Kim D, Trautmann M, Johns D, Festa A.
Long-term treatment with exenatide improved postprandial glycaemic control and was associated with a shift from small to large HDL and LDL particles.
Diabetologia 49 (Suppl1):0224, 2006

Abstracts

1. Heinemann L, **Kapitza C**, Starke AAR, Heise T.
Wirkungsdauer des Insulinanalogons B28Asp im Vergleich zu kurzwirkendem Insulin
Diabetes und Stoffwechsel 5 (Sonderheft):79, 1996
2. Heinemann L, **Kapitza C**, Starke AAR, Heise T.
Duration of action of the insulin analogue B28Asp in comparison to regular insulin
Diabetes 45 (Suppl2):139A, 1996
3. Weyer C, **Kapitza C**, Starke AAR, Heise T, Heinemann L.
Duration of action of the insulin analogue B28Asp in comparison to regular insulin.
Diabetologia 39 (Suppl1):A24, 1996
4. **Kapitza C**, Heise T, Pfützner A, Steiner S, Heinemann L, Rave K.
Dose-response characteristics for a new pulmonary insulin formulation and inhaler
Diabetologia 43 (Suppl1):A46, 2000
5. **Kapitza C**, Heise T, Heinemann L, Shapiro DA, Gopalakrishnan V, Fishman RS.
Impact of particle size and aerosolization time on the metabolic effect of an inhaled insulin aerosol.
Diabetes 50 (Suppl2):A118, 2001
6. Heinemann L, **Kapitza C**, Heise T, Shapiro DA, Gopalakrishnan V, Fishman RS.
Impact of particle size and aerosolization time on the metabolic effect of an inhaled insulin aerosol.
Diabetologia 44 (Suppl1):A5, 2001
7. **Kapitza C**, Nosek L, Lindholm A, Leth G, Codony SG, Heise TC.
Postprandial Dosing of the "Lowmix" Biphasic Insulin Aspart.
Diabetologia 44 (Suppl1):A211, 2001
8. Hompesch M, **Kapitza C**, Scharling B, Thomsen LK, Heise T.
Intra-Subject Variability of Pulmonary Insulin via the AERx[®] Insulin Diabetes Management System versus Subcutaneous Insulin.
Diabetologia 44 (Suppl1):A212, 2001
9. **Kapitza C**, Nosek L, Lindholm A, Leth G, Codony SG, Heise T.
Biphasic Insulin Aspart Provides Good Metabolic Control Even When Injected Postprandially.
Diabetes 50 (Suppl2):A118, 2001
10. Perera A, **Kapitza C**, Nosek L, Heinemann L, Shapiro DA, Fishman RS, Heise T.
Reproducibility of inhaled and subcutaneous insulin in Type 2 diabetic patients.
Diabetologia 44 (Suppl1):A212, 2001

11. **Kapitza C**, Nosek L, Leth G, Codony SG, Lindholm A, Heise T.
Biphasic Insulin Aspart provides good metabolic control even when injected postprandially.
Diabetes und Stoffwechsel 10 (Suppl1):67, 2001
12. **Kapitza C**, Trautmann ME, Heise T, Heinemann L, Patterson B.
Daily administration of LY307161 SR (GLP-1 Analog) normalizes blood glucose in type 2 diabetes
Diabetes 51 (Suppl2):A84, 2002
13. **Kapitza C**, Hompesch M, Thomsen LK, Heise T.
Intra-Subject Variability of Pulmonary Insulin via the AERx[®] Insulin Diabetes Management System Versus Subcutaneous Insulin.
Diabetes 51 (Suppl2):A103, 2002
14. Trautmann ME, **Kapitza C**, Mace KF, Patterson B, Hompesch M, Heise T.
LY307161 SR, a Sustained Release Formulation of a GLP-1 Analog, Is Suitable for Once Daily Administration in Patients with Type 2 Diabetes.
Diabetes 51 (Suppl2):A135, 2002
15. Djurhuus CB, Jungheim K, Gravholt CH, **Kapitza C**, Wientjes KJ, Koschinsky T, Heinemann L, Christiansen JS.
Subcutaneous continuous glucose monitoring reveals insight into long-term management of diabetes through a tight correlation of time spent in hyperglycemia with HbA1c
Diabetes 51 (Suppl2):A96, 2002
16. **Kapitza C**, Hompesch M, Thomsen LK, Heise T.
Intra-Subject Variability of Pulmonary Insulin via the AERx[®] Insulin Diabetes Management System Versus Subcutaneous Insulin.
Diabetes und Stoffwechsel 11 (Suppl1):77, 2002
17. Jungheim K, **Kapitza C**, Djurhuus CB, Wientjes KJ, Koschinsky T.
Blutglucose-Änderungsgeschwindigkeit unter Alltagsbedingungen bei Personen mit Diabetes mellitus Typ 1: eine Analyse anhand mehrtägiger kontinuierlicher Glucoseprofile.
Diabetes und Stoffwechsel 11 (Suppl1):80, 2002
18. Trautmann ME, **Kapitza C**, Hompesch M, Heise T, Mace KF, Patterson B.
Once daily administration of LY307161 SR, a sustained release formulation of a Glp-1 Analogue, substantially reduces fasting and daytime glucose levels in patients with Type 2 diabetes.
Diabetologia 45 (Suppl2):121, 2002
19. Poll LW, **Kapitza C**, Wittsack H, Koch J, Heinemann L, Hompesch M, Mödder U, Rave K.
Abdominal fat volumes in patients with diabetes: rapid and reliable determination by means of magnetic resonance imaging.
Diabetologia 45 (Suppl2):687, 2002

20. Jungheim K, **Kapitza C**, Djurhuus CB, Wientjes KJ, Koschinsky T, Glucose Monitoring Study Group.
How rapid does blood glucose concentration change in daily-life of patients with Type 1 diabetes?
Diabetologia 45 (Suppl2):855, 2002
21. Caduff A, **Kapitza C**, Dewarrat R, Hirt E, Heinemann L.
Non-invasive, continuous glucose monitoring system based on impedance spectroscopy: A proof of concept study.
Diabetologia 45 (Suppl2):865, 2002
22. Djurhuus CB, Jungheim K, Gravholt CH, **Kapitza C**, Wientjes K, Koschinsky T, Heinemann L, Christiansen JS, Glucose Monitoring Study Group.
Subcutaneous continuous glucose monitoring reveals insight into long-term management of diabetes through a tight correlation of time spent in hyperglycemia vs. HbA1c.
Diabetologia 45 (Suppl2):866, 2002
23. Heise T, Nosek L, Draeger E, Biilmann Ronn B, **Kapitza C**, Heinemann L.
Lower within-subject variability of insulin detemir compared to NPH insulin and insulin glargine in subjects with Type 1 diabetes.
Diabetologia 46 (Suppl2):12, 2003
24. **Kapitza C**, Arbit E, Abbas R, Goldberg M, Hompesch M, Heinemann L, Heise T.
Oral insulin: proof of concept in Type 2 diabetic patients.
Diabetologia 46 (Suppl2):16, 2003
25. Caduff A, Buschor S, Dewarrat R, Schrepfer T, Nosek L, Heise T, **Kapitza C**, Heinemann L.
Evaluation of a non-invasive, continuous glucose monitoring system in patients with diabetes: results of a glucose clamp study with hypoglycaemic and hyperglycaemic excursions.
Diabetologia 46 (Suppl2):121, 2003
26. Trautmann ME, Chen C-F, Chappell JC, Dananberg J, Patterson B, Klausmann G, **Kapitza C**.
LY307161 SR, a long-acting GLP-1 analog, improved glycemic control in patients with Type 2 diabetes.
Diabetologia 46 (Suppl2):174, 2003
27. **Kapitza C**, Arbit E, Abbas R, Goldberg M, Hompesch M, Heinemann L, Heise T.
Oral Insulin: Proof of Concept in Type 2 Diabetic Patients.
Diabetes 52 (Suppl1):159-OR, 2003
28. Caduff A, **Kapitza C**, Dewarrat R, Buschor S, Schrepfer T, Heinemann L.
Evaluation of a Non-Invasive, Continuous Glucose Monitoring System in Patients with Diabetes : Results of a Glucose Clamp Study.
Diabetes 52 (Suppl1):390-P, 2003

29. **Kapitza C**, Heise T, McGovern M, Cefali E,, Buchwald A, Heinemann L, Hompesch M.
Time-Action Profile of a New Pulmonary Insulin Applied with a Metered-Dose Inhaler.
Diabetes 52 (Suppl1):449-P, 2003
30. Heise T, Nosek L, Draeger E, Stender A, Biilmann Ronn B, **Kapitza C**, Heinemann L.
Lower within-Subject Variability of Insulin Detemir in Comparison to NPH Insulin and Insulin Glargine in Subjects with Type 1 Diabetes.
Diabetes 52 (Suppl1):518-P, 2003
31. Trautmann M, Chen C-F, Chappell J, Dananberg J, Patterson B, Klausmann G, **Kapitza C**, the CFFH Study Group.
LY307161 SR, a Long-Acting GLP-1 Analog, Improved Glycemic Control in Patients with Type 2 Diabetes.
Diabetes 52 (Suppl1):582-P, 2003
32. Rave K, Nosek L, Heinemann L, Becker R, Frick A, Poll L, **Kapitza C**.
Influence of Abdominal Fat Volume on Pharmacodynamics of sc Injected Regular Human Insulin in Patients with Type 2 Diabetes.
Diabetes 52 (Suppl1):1301-P, 2003
33. Poll L, **Kapitza C**, Wittsack H-J, Heinemann L, Hompesch M, Moedder U, Rave K.
Abdominal Fat Volume in Patients with Diabetes: Rapid and Reliable Determination by Means of a Novel Magnetic Resonance Imaging Analysis Method
Diabetes 52 (Suppl1):1679-P, 2003
34. Caduff A, **Kapitza C**, Dewarrat R, Heinemann L.
Non-Invasive, Continuous Glucose Monitoring System: Evaluation by Means of Glucose Clamps.
Diabetes 52 (Suppl1):1879-PO, 2003
35. Heise T, Nosek L, Biilmann Ronn B, Endahl L, Heinemann L, **Kapitza C**, Draeger E.
Intra-individuelle Variabilität von Basalinsulinen: Vorteile von Insulin Detemir gegenüber NPH-Insulin und Insulin Glargin bei Patienten mit Typ-1-Diabetes.
Diabetes und Stoffwechsel 13:V-63, 2004
36. Arbit E, Nosek L, **Kapitza C**, Beckett P, Gelfand R, Goldberg M, Heise T.
Oral insulin as first-line therapy in Type 2 diabetes: a randomized-controlled pilot study.
Diabetologia 47 (Suppl1):8, 2004
37. **Kapitza C**, Becker RHA, Frick AD, Heise T, Rave K.
Pharmacodynamics and pharmacokinetics of insulin glulisine compared with insulin lispro and regular human insulin in patients with Type 2 diabetes.
Diabetologia 47 (Suppl1):733, 2004

38. Nosek L, Becker RHA, Frick AD, **Kapitza C**, Heise T, Rave K.
Prandial blood glucose control with pre- and post-meal insulin glulisine versus regular human insulin.
Diabetologia 47 (Suppl1):834, 2004
39. Heinemann L, Rave K, Kronshage B, Nosek L, Heise T, **Kapitza C**, Ward K, Sass D, Essenpreis M, Voelkel D, Lodwig V.
Continuous glucose monitoring for 5 days using a novel glucose-electrode in patients with Type 1 diabetes.
Diabetologia 47 (Suppl1):855, 2004
40. Poll LW, Wittsack H-J, Willers R, Mödder U, Heinemann L, **Kapitza C**, Rave K.
Correlation Between Anthropometric Parameters and Abdominal Fat Volumes Assessed by a Magnetic Resonance Imaging Method in Patients with Diabetes.
Diabetes Technology & Therapeutics 6:844-849, 2004
41. Becker RHA, Frick AD, **Kapitza C**, Heise T, Rave K.
Pharmacodynamics (PD) and Pharmacokinetics (PK) of Insulin Glulisine Compared with Insulin Lispro (IL) and Regular Human Insulin (RHI) in Patients with Type 2 Diabetes.
Diabetes 53 (Suppl2):503-P, 2004
42. Nosek L, Becker RHA, Frick AD, **Kapitza C**, Heise T, Rave K.
Prandial Blood Glucose Control with Pre- and Post-Meal Insulin Glulisine Versus Regular Human Insulin.
Diabetes 53 (Suppl2):588-P, 2004
43. Heise T, Nosek L, Arbit E, Beckett P, Gelfand R, Porter KM, Goldberg M, **Kapitza C**.
Reduction of Postprandial Blood Glucose Excursions by an Optimized Formulation of Oral Insulin.
Diabetes 54 (Suppl1):418-P, 2005
44. Heise T, Nosek L, Arbit E, Beckett P, Gelfand R, Porter KM, Goldberg M, **Kapitza C**.
Reduction of Postprandial Blood Glucose Excursions by an Optimized Formulation of Oral Insulin.
Diabetologia 48 (Suppl1):77, 2005
45. Heise T, Kapitza C, Jacobsen LV, Brøndsted L, Heinemann L.
Pharmacokinetic and pharmacodynamic differences between premixed suspensions of insulin aspart: biphasic insulin aspart 30, 50 and 70.
Diabetologia 48 (Suppl1):829, 2005
46. Heise T, **Kapitza C**, Nosek L, Beckett P, Gelfand R, Goldberg M, Arbit E.
Oral insulin as first-line therapy in type 2 diabetes: A randomized-controlled pilot study. Diabetes und Stoffwechsel 14 (Suppl1):P-198, 2005

47. Heinemann L, Dellweg S, Nosek L, Brandt D, Essenpreis M, Koschinsky T, **Kapitza C**.
Alternate Site (like) Phenomenon: Rapid Changes from Hypoglycemic to Hyperglycemic Levels in a Clinical-Experimental Study in Patients with T1D.
Diabetes 55 (Suppl1):395-P, 2006
48. **Kapitza C**, Heise T, Klein O, Granger C, Jallet K, Obach R, Ramis J, Prunyonosa J.
BIM51077, a Novel GLP-1 Analog, Achieves Sustained Improvement in Blood Glucose Control over 28 Days of Treatment.
Diabetes 55 (Suppl1):500-P, 2006
49. **Kapitza C**, Heise T, Klein O, Granger C, Jallet K, Obach R, Ramis J, Prunyonosa J.
BIM51077, a Novel GLP-1 Analog, Showed Linear PK and Dose-Response Relationship over 7 Days of Treatment.
Diabetes 55 (Suppl1):2019-PO, 2006
50. Pettis RJ, Hompesch M, **Kapitza C**, Harvey NG, Ginsberg B, Heinemann L.
Intra-Dermal Insulin Lispro Application with a New Microneedle Delivery System Led to a Substantially More Rapid Insulin Absorption Than Subcutaneous Injection.
Diabetes 55 (Suppl1):108-OR, 2006
51. Dellweg S, Nosek L, **Kapitza C**, Brandt D, Essenpreis M, Koschinsky T, Heinemann L.
Alternate site (like) phenomenon: rapid changes from hypoglycaemic to hyperglycaemic glucose levels in a clinical-experimental study in patients with type 1 diabetes.
Diabetologia 49 (Suppl1): 0968, 2006
52. Heinemann L, Hompesch M, **Kapitza C**, Harvey NG, Ginsberg BH, Pettis RJ.
Intra-dermal insulin lispro application with a new microneedle delivery system led to a substantially more rapid insulin absorption than subcutaneous injection.
Diabetologia 49 (Suppl1):1014, 2006
53. Nosek L, Becker RH, Frick AD, **Kapitza C**, Heise T, Rave K.
Prandiale Blutzucker Kontrolle mit vor und nach einer Mahlzeit injiziertem Insulinglulisin im Vergleich zu Normalinsulin.
Diabetologie und Stoffwechsel (Suppl1):182, 2006
54. **Kapitza C**, Becker RH, Frick AD, Heise T, Rave K.
Pharmakodynamik und Pharmakokinetik von Insulinglulisin im Vergleich mit Insulinlispro und Normalinsulin bei Patienten mit Typ 2 Diabetes.
Diabetologie und Stoffwechsel 1 (Suppl1):189, 2006

55. **Kapitza C**, Nosek L, Arbit E, Beckett P, Gelfand R, Porter KM, Goldberg M, Heise T.
Reduction of postprandial blood glucose excursions by an optimised formulation of oral insulin.
Diabetologie und Stoffwechsel (Suppl1):222, 2006
56. Heinemann L, Dellweg S, Nosek L, **Kapitza C**, Brandt D, Essenpreis M, Koschinsky T.
Alternate site (like) phenomenon: rapid changes from hypoglycaemic to hyperglycaemic glucose levels in a clinical-experimental study in patients with type 1 diabetes.
Diabetologie und Stoffwechsel (Suppl1):376, 2006
57. **Kapitza C**, Hövelmann U, Nosek L, Brandt D, Essenpreis M, Heinemann L.
Continuous Glucose Monitoring before and after Exercise in Patients with Type 1 Diabetes on CSII.
Diabetes 56 (Suppl1):0406-P, 2007
58. Strange P, **Kapitza C**, Schleusener D, Fein S.
Glycemic Control with the Basal/Bolus Insulin Delivery System h-PATCH™ Measured by Continuous Glucose Monitoring System (CGMS) in Patients with Type 2 Diabetes Mellitus.
Diabetes 56 (Suppl1):0454-P, 2007
59. Heinemann L, Hövelmann U, Nosek L, Brandt D, Essenpreis M, **Kapitza C**.
Continuous glucose monitoring before and after exercise in patients with type 1 diabetes on CSII
Diabetologie und Stoffwechsel (Suppl1):P179, 2007
60. Bonadonna RC, **Kapitza C**, Heise T, Avogaro A, Boldrin M, Grimsby J, Mulligan M, Zhi J, Arbet-Engels C, Balena R.
Glucokinase Activator RO4389620 Improve Plasma Glucose Concentrations, Beta-Cell Function, Endogenous Glucose Output and Glucose Utilization in Patients with Tyoe 2 Diabetes
Diabetes 57, (Suppl1): 0332-OR, 2008
61. **Kapitza C**, Klein O, Obach R, Birman P, Jallet K, Balena R.
Long Acting Human GLP-1 Analogue R1583: Safety; pharmacokinetic and Pharmacodynamic Properties after a Single Administration in Subjects with Type 2 Diabetes
Diabetes 57, (Suppl1): 0506-P, 2008
62. Flint A, **Kapitza C**, Hindsberger C, Zdravkovic M.
The Once-Daily Human GLP-1 Analogue Liraglutide Decreases Postprandial Hunger and Energy Intake
Diabetes 57, (Suppl1): 0555-P, 2008

63. Flint A, **Kapitza C**, Hindsberger C, Zdravkovic M.
The Once-Daily Human GLP-1 Analogue Liraglutide Improves both Absolute and Baseline Corrected Postprandial Glucose Levels
Diabetes 57, (Suppl1): 0556-P, 2008
64. **Kapitza C**, Flint A, Hindsberger C, Zdravkovic M.
The Effect of the Once-Daily Human GLP-1 Analogue Liraglutide on the Pharmacokinetics of Paracetamol
Diabetes 57, (Suppl1): 2145-PO, 2008
65. **Kapitza C**, Flint A, Spitzer H, Hindsberger C, Zdravkovic M.
The Effect of Different Injection Sites on the Pharmacokinetics of the Once-Daily Human GLP-1 Analogue Liraglutide
Diabetes 57, (Suppl1): 2146-PO, 2008
66. Flint A, **Kapitza C**, Hindsberger C, Zdravkovic M.
The once-daily human GLP-1 analogue liraglutide improves both absolute and baseline corrected postprandial glucose levels
Diabetologia 57, (Suppl1): 0887, 2008
67. Horowitz M, Flint A, Doran S, Rasmussen MF, **Kapitza C**, Andreasen AH, Jones KL, Zdravkovic M, Chapman IM.
Effects of the once-daily human GLP-1 analogue liraglutide on appetite and energy intake in type 2 diabetes
Diabetologia 57, (Suppl1): 0889, 2008
68. Bonadonna RC, **Kapitza C**, Heise T, Avogaro A, Boldrin M, Grimsby J, Mulligan M, Zhi J, Arbet-Engels C, Balena R.
Glucokinase activator RO4389620 improves beta cell function and plasma glucose fluxes in patients with type 2 diabetes
Diabetologia 57, (Suppl1): 0927, 2008
69. Jax T, Nosek L, Hövelmann U, Hermanski L, **Kapitza C**, Heise T, Heinemann L.
Systematic Evaluation of the Influence of Hyperglycemia on Diastolic Myocardial Function.
Diabetes 58 (Suppl1): 2158-PO, 2009
70. Arnolds S, Dellweg S, Clair J, Dain MP, Nauck MA, Rave K, **Kapitza C**.
Insulin Glargine (GLAR) + Metformin (MET): An Efficacious and Safe Regimen That Can Be Combined with Exenatide (EXE) or Sitagliptin (SITA).
Diabetes 58 (Suppl1): 526-P, 2009
71. Dobbins RL, Kapur A, **Kapitza C**, O'connor-Semmes RL, Wenli Tao, Hussey EK.
Remogliflozin Etabonate, a Selective Inhibitor of the Sodium-Glucose Transporter 2 (SGLT2) Reduces Serum Glucose in Type 2 Diabetes Mellitus (T2DM) Patients.
Diabetes 58 (Suppl1): 573-P, 2009

72. Pettis RJ, Hirsch LJ, Nosek L, **Kapitza C**, Sutter DE, Harvey NG.
Microneedle-based intradermal injection of lispro or human regular insulin accelerates insulin uptake and reduces post-prandial glycaemia.
Diabetologia 52 (Suppl1): 963, 2009
73. Heinemann L, Nosek L, **Kapitza C**, Schweitzer MA, Stephan P, Grunder A, Krinelke L.
Changes in Basal Insulin Infusion Rates with CSII: Time until a Change in Metabolic Effect Is Induced in Patients with Type 1 Diabetes.
Diabetes 58 (Suppl1):230-OR, 2009
74. Heinemann L, Nosek L, **Kapitza C**, Schweitzer MA, Krinelke L.
Changes in basal insulin infusion rates with subcutaneous insulin infusion: time until a change in metabolic effect is induced in patients with type 1 diabetes.
Diabetes Care 32(8):1437-9, 2009
75. Becker Reinhard H.A., Ruus P, Liu Y-H, **Kapitza C**.
Restoration of Insulin Release with Lixisenatide in Patients with Type 2 Diabetes
Diabetes 59 (Suppl1):552-P,2010
76. Pellanda Carolina, Mangold B, Schulte M, Niggli M, **Kapitza C**.
Effect of Taspoglutide, a Human GLP-1 Analog, on Insulin Secretion in Patients (pts) with Type 2 Diabetes (T2D)
Diabetes 59 (Suppl1):588-P,2010
77. Jax T, **Kapitza C**, Nilsson S, Breuer O.
The Effect of KB003305, a Liver-Targeted Glucocorticoid Receptor Antagonist, on Fasting Plasma Glucose and Oral Glucose Tolerance after Multiple Oral Doses in Patients with Diabetes Type 2
Diabetes 59 (Suppl1):605-P,2010
78. **Kapitza C**, Jax T, Nilsson S, Breuer O.
KB003305, a Liver-Targeted Glucocorticoid Receptor Antagonist: A First-In-Man Study To Investigate Safety, Tolerability, Pharmacodynamics, of Single Oral Doses in Healthy Male Volunteers
Diabetes 59 (Suppl1):694-P,2010
79. Becker Reinhard H.A., Ruus P, Liu Y-H, **Kapitza C**.
Restoration of Insulin Release with Lixisenatide in Patients with Type 2 Diabetes
Diabetologia 53 (Suppl1): 0850, 2010